Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • BiondVax Pharmaceuticals Ltd ADR News

    0,45 $ -4,74% -0,0224 $
    In : 0,4197 € | 25.04.24 22:00:04 Nasdaq aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A3DZ0C
    ISIN: US09073Q2049
    US-Symbol: SCNI
    Typ: Aktie

    BiondVax Pharmaceuticals Ltd ADR News

    21.11.22 - PR Newswire
    BiondVax CEO to Present at the January 2023 Biotech Showcase in San Francisco
    BiondVax CEO to Present at the January 2023 Biotech Showcase in San Francisco PR Newswire
    03.11.22 - PR Newswire
    BiondVax to present at Recent Advances in Fermentation Technology (RAFT) 14 Conference
    BiondVax to present at Recent Advances in Fermentation Technology (RAFT) 14 Conference PR Newswire
    02.11.22 - PR Newswire
    BiondVax provides plan to address Nasdaq compliance
    BiondVax provides plan to address Nasdaq compliance PR Newswire
    11.10.22 - PR Newswire
    BiondVax to present at LD Micro Investor Conference in Los Angeles
    BiondVax to present at LD Micro Investor Conference in Los Angeles PR Newswire
    30.09.22 - PR Newswire
    BiondVax announces financial plans to support its ongoing NanoAb pipeline development
    BiondVax announces financial plans to support its ongoing NanoAb pipeline development PR Newswire
    20.09.22 - PR Newswire
    BiondVax's Strategic Research Collaboration with Max Planck and UMG: Significant progress towards development of innovative nanosized antibodies (NanoAbs) for therapeutic indications in addition to COVID-19
    BiondVax's Strategic Research Collaboration with Max Planck and UMG: Significant progress towards development of innovative nanosized antibodies (NanoAbs) for therapeutic ...
    08.09.22 - PR Newswire
    BiondVax to Present at H.C. Wainwright 24th Annual Global Investment Conference
    BiondVax to Present at H.C. Wainwright 24th Annual Global Investment Conference PR Newswire
    25.08.22 - PR Newswire
    BiondVax announces Second Quarter 2022 Financial Results and Provides Business Update
    BiondVax announces Second Quarter 2022 Financial Results and Provides Business Update PR Newswire
    10.08.22 - PR Newswire
    BiondVax and European Investment Bank sign definitive amendment extending maturity of loan until December 2027 with additional terms in support of BiondVax's new strategy
    BiondVax and European Investment Bank sign definitive amendment extending maturity of loan until December 2027 with additional terms in support of BiondVax's new strategy PR ...
    07.06.22 - PR Newswire
    BiondVax receives supportive Scientific Advice from the Paul Ehrlich Institute (PEI) for COVID-19 NanoAb development plans including first-in-human Phase 1/2a safety and efficacy clinical trial
    BiondVax receives supportive Scientific Advice from the Paul Ehrlich Institute (PEI) for COVID-19 NanoAb development plans including first-​in-human Phase 1/2a safety and efficacy ...
    01.06.22 - PR Newswire
    BiondVax Announces First Quarter 2022 Financial Results and Provides Business Update
    BiondVax Announces First Quarter 2022 Financial Results and Provides Business Update PR Newswire
    19.05.22 - PR Newswire
    BiondVax to Present at H.C. Wainwright Global Investment Conference
    BiondVax to Present at H.C. Wainwright Global Investment Conference PR Newswire
    12.05.22 - PR Newswire
    BiondVax Provides Update at Biomed Israel Conference and Announces Significant Progress in its Nanosized Antibodies Program
    BiondVax Provides Update at Biomed Israel Conference and Announces Significant Progress in its Nanosized Antibodies Program PR Newswire
    09.05.22 - PR Newswire
    BiondVax to Present at this week's Biomed Israel Conference
    BiondVax to Present at this week's Biomed Israel Conference PR Newswire
    05.04.22 - PR Newswire
    BiondVax to host a Hebrew-language analyst and investor webinar on April 6th
    BiondVax to host a Hebrew-​language analyst and investor webinar on April 6th PR Newswire
    31.03.22 - PR Newswire
    BiondVax to host analyst and investor webinar on April 4th
    BiondVax to host analyst and investor webinar on April 4th PR Newswire
    28.03.22 - PR Newswire
    BiondVax Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
    BiondVax Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update PR Newswire
    24.03.22 - PR Newswire
    Thinking about buying stock in Nikola Corp, D-Market Electronic Services, Biondvax Pharmaceuticals, Trip.com, or Spectrum Pharmaceuticals?
    Thinking about buying stock in Nikola Corp, D-Market Electronic Services, Biondvax Pharmaceuticals, Trip.com, or Spectrum Pharmaceuticals? PR Newswire
    24.03.22 - PR Newswire
    BiondVax signs definitive collaboration agreement for the development of a pipeline of innovative nanosized antibody (NanoAb) therapies
    BiondVax signs definitive collaboration agreement for the development of a pipeline of innovative nanosized antibody (NanoAb) therapies - Broad collaboration with Max Planck ...
    14.03.22 - PR Newswire
    European Investment Bank Agrees in Principle to Extend the Maturity of its Loan until December 2027 with Additional Terms that Provide Continued Long-Term Support for BiondVax's New Strategy
    European Investment Bank Agrees in Principle to Extend the Maturity of its Loan until December 2027 with Additional Terms that Provide Continued Long-Term Support for ...

    Newssuche

    Videos

    newspaper
    25.04.24 +21,95%
    Technical Trading: S&P 500 Short Chance
    S&P 500 Short Typ: Turbo Open End WKN: NG8FUZ Hebel: 31 Laufzeit: OpenEnd Einstieg: Market ... Mehr »